T

Telomir Pharmaceuticals Inc
NASDAQ:TELO

Watchlist Manager
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Watchlist
Price: 4.27 USD -0.7%
Market Cap: 126.4m USD
Have any thoughts about
Telomir Pharmaceuticals Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-6.4
Current
-8.4
Median
13.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-6.4
=
Enterprise Value
126.5m USD
/
EBITDA
-19.8m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
T
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Average EV/EBITDA: 459.7
Negative Multiple: -6.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.4
42%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.5
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.8
18%
9.4
CH
Novartis AG
SIX:NOVN
9.6
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A